News | Magnetic Resonance Imaging (MRI) | November 02, 2016

Brain Volume May Help Predict Who Will Develop Dementia with Lewy Bodies

Using MRI brain scans to assess shrinkage of hippocampus could help predict dementia with Lewy bodies versus Alzheimer’s disease

MRI, brain scans, shrinkage, dementia with Lewy bodies, Alzheimer's disease, Neurology journal study

November 2, 2016 — Lack of shrinkage in the area of the brain responsible for memory may be a sign people with thinking and memory problems may go on to develop dementia with Lewy bodies rather than Alzheimer’s disease, according to a new study. Shrinkage in this hippocampus area of the brain is an early sign of Alzheimer’s disease.

The study was published in the Nov. 2, 2016, online issue of Neurology, a medical journal of the American Academy of Neurology.

Dementia with Lewy bodies is a common form of dementia. Because it has many symptoms in common with Alzheimer’s and Parkinson’s disease, it can be difficult to diagnose. It can include movement problems, sleep disorders and hallucinations.

“Being able to identify people who are at risk for dementia with Lewy bodies is important so they can receive the correct treatments early on,” said study author Kejal Kantarci, M.D., MS, of the Mayo Clinic in Rochester, Minn., and a member of the American Academy of Neurology. “Early diagnosis also helps doctors know what drugs to avoid — up to 50 percent of people with dementia with Lewy bodies have severe reactions to antipsychotic drugs.”

For the study, 160 people with thinking and memory problems, called mild cognitive impairment, had brain magnetic resonance imaging (MRI) scans at the start of the study to measure the size of the hippocampus. They also had yearly tests for an average of two years. During that time, 61 people, or 38 percent, developed Alzheimer’s disease and 20 people, or 13 percent, progressed to probable dementia with Lewy bodies. It is called probable dementia with Lewy bodies because the disease can be diagnosed definitively only by an autopsy after death.

The people who had no shrinkage in the hippocampus were 5.8 times more likely to develop probable dementia with Lewy bodies than those who had hippocampal shrinkage. A total of 17 out of the 20, or 85 percent, of people who developed dementia with Lewy bodies had a normal hippocampus volume; while 37 of the 61, or 61 percent, of people who developed Alzheimer’s disease had shrinkage in the hippocampus.

The relationship was even stronger when researchers looked only at people whose thinking problems did not include memory issues. Dementia with Lewy bodies does not always affect memory; thinking skills that are affected usually include attention, problem solving and the ability to interpret visual information.

Kantarci noted that diagnosis of dementia with Lewy bodies and Alzheimer’s disease can also be difficult because some people have signs of both diseases in their brains. She said this research should be confirmed with studies that use autopsies for final diagnoses.

The study was supported by the National Institutes of Health, Mangurian Foundation and Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program.

For more information: www.neurology.org

Related Content

Life Image and Mendel.ai Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and Mendel.ai announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more